A Trial of AK104 Plus Anlotinib in NSCLC

NCT04646330 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
114
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Akeso